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Poster Session-I 79serotherapy alone, 6 pts with reduced intensity regimens, and 3
pts received no conditioning. Median age at the second SCT
was 6.2 years (range, 0.3–14.2 years) and the median time from
the first SCT to the second SCT was 10.3 months (range, 1.2–
84 months).
Results: 40 patients had initial engraftment, median time to ANC
$ 500  106/l was 19 days (range, 9–28 days), and median time to
a platelet count $ 20  109/l was 26.5 days (range, 10–100 days).
Acute grade $ 3 GVHD, developed in 7 pts (13.7%), mild VOD
of the liver developed in 2 pts (3.9%).The 10-year overall (OS) and
event free survival (EFS) were 66% and 50% respectively. When sur-
vival was evaluated by the interval between the 1st and 2nd SCT:\6
months (19 pts) and $ 6 months (32 pts), the 10-year OS was 55%
and 73% for the 2 cohorts respectively (P 5 0.05), and the 10-year
EFS was 27% and 67% for the 2 cohorts respectively (P 5 0.005).
With intervals of\ 12 months (26 pts) and $ 12 months (25 pts),
the 10-year OS was 64% and 70% for the 2 cohorts respectively
(P 5 0.4), and the 10-year EFS was 42% and 63% for the 2 cohorts
respectively (P 5 0.2). When survival was evaluated by underlying
disease, the 10-year OS was 59%, 75% and 59% for pts
with NMHD, IMD and leukemia respectively (P 5 0.3), and the
10-year EFS was 55%, 50%, and 59% (P5 0.5) for the same groups
respectively.
Conclusions: Second SCT in children is relatively well tolerated
and is associated with reasonable survival. OS and EFS appear to be
considerably better when the interval between the 2 transplants is$
6 months.214
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Objective: Hematopoietic stem cell transplantation (HSCT) is
the only curative treatment of some congenital immunodefi-
ciency diseases especially leukocyte adhesion deficiency type-I
(LAD-I).
Methods: Six patients (3 girls, 3 boys), received allogeneic HSCT
between 2007 and 2008. One patient received stem cell from her
healthy full human leukocyte antigen (HLA) matched sibling, three
patients from their full matched other related (one from father, one
from mother and one from uncle which verified with high resolution
HLA matching method), one patient from his mother (haploidenti-
cal) and one patient from his father with one antigen mismatch. The
graft source was bone marrow in 4 patients and peripheral blood
stem cells (PBSC) in others. Median age at HSCT was 17 months
(10.2–87.8 months). All patients were conditioned with Fludarabine,
Melfalan and Antithymocyte globulin (ATG). For graft-versus-host
disease (GVHD) prophylaxis, we used Cyclosporine and Methyl-
prednisolone.
Results: All patients engrafted. Median time of Absolute Neutro-
phil Count $ 0.5109 /L was 113 and median time of Platelet re-
covery $20109 /L was 116. Median follow-up of patients was 8
months (range, 1–20 months) and at present five (83%) patients
are alive with sustained engraftment and without recurrent infection
and improvement of their failure to trive. Three patients developed
acute GVHD after transplantation that one of them died because of
acute GVHD one month after transplantation. No chronic GVHD
occurred. Full chimerism was achieved in one patient and mixed chi-
merism was achieved in four patients.
Conclusions: Early diagnosis and HSCT of LAD-I rescue
patients from lethal disease but not all of patients have full match
siblings and others must transplanted from other related, haploi-
dentical relative, non relative full match or cord blood. Analysis
of our patients who developed mixed chimerism suggested that
this mixed chimeric state resulted in a reversal of the LAD-I
phenotype.215
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Allosensitization due to transfusion therapy has been a barrier to
engraftment in patients with sickle cell (SC) disease, requiring the
use of more intense conditioning. In a mouse model, sensitization
to bone marrow cells (BMC) results predominantly from the hu-
moral immune response. We added alemtuzumab (anti-CD52) lym-
phodepletion for conditioning recipients for a hematopoietic cell
transplant. 2 cycles of alemtuzumab were administered with the ra-
tionale of eliminating memory B cells by inducing them to undergo
homeostatic proliferation after the 1st round of depletion. Condi-
tioning consisted of alemtuzumab (10 mg/day, days -53— -50 and
days -24 —-21), fludarabine (30 mg/m2/day days -5 —-3), 200 cGy
TBI (day -1), matched related donor BM infusion day 0, followed
by cyclosporine and mycophenolate mofetil (day-1—.10 months).
2 patients have been transplanted. Patient 1 was 7 at transplant,
with a history of multiple pain crises, episodes of acute chest syn-
drome, and extensively treated with exchange transfusion therapy
and hydroxyurea. She received 14.5  106kg CD34 cells from her
HLA-identical sibling donor with SC trait, showing 78% donor en-
graftment day 30. Her RBC production remained phenotypically
trait which is compatible with donor hematopoiesis . 615 days
post-transplant, with donor lymphoid and myeloid chimerism con-
sistently 20–30%. Immunosuppression was discontinued 10 months
post-stem cell transplantation (SCT). Patient 2 was 9 at transplant
with multiple pain crises, 2 episodes of acute chest syndrome before
transplant, and had been treated with exchange transfusions for 7
years. He received HLA-matched sibling donor BM, processed to
deplete T- and B cells. The graft contained 5.24  106/kg CD34,
0.55  106/kg ab-TCR and 0.35  106/kg FC cells. He has been
transfusion-independent post-SCT, with 100% donor RBC produc-
tion and chimerism levels at 20–30% donor by FISH .851 days
post-transplant. Immunosuppression was discontinued at 23 months
post-SCT. Neither patient had GVHD, transplant-related toxicity,
or SC complications since transplant. Data suggest that the addition
of an alemtuzumab split-course to a nonmyeloablative transplant
regimen allows hematopoietic cell engraftment of allosensitized re-
cipients with SCD without GVHD. Stable mixed chimerism of my-
eloid and lymphoid lineages is accompanied by full donor
erythropoiesis. Stable mixed chimerism may also have been achieved
due to prolonged post-SCT immunosuppression from MMF.216
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Introduction: Hematopoietic stem cell transplantation (HSCT)
has been associated with decreased food intake, malnutrition, re-
duced lean body mass and reduced bone mineral density (BMD),
which might result in increased morbidity and mortality. The pur-
pose of this study was to evaluate the BMD, lean body mass, calcium
and vitamin D intake in children and adolescents before and 6
months after HCT.
Patients andMethods:Forty patients (25 boys and 15 girls; mean
age: 10,16 4,26 yrs) who were consecutively submitted to allogenic
HSCT between September 2006 and March 2008 and survived after
6 months were included in the analysis. BMD was evaluated by DXA
(HOLOGIC-1000) at the lumbar spine (LS) and whole body (WB),
lean body mass by bioelectrical impedance analysis and food intake
by a 24 hours recall and food frequency questionnaire.
Results: LS BMD was 0,6736 0,167 g/cm2 in the first evaluation
and 0,6626 0,78 g/cm2 in the second evaluation (p. 0.05). The WB
BMD was 0,850 6 0,164g/cm2 in the first evaluation, reducing to
